Filing Flows › Northwest Biotherapeutics (NWBO) › R&D spending
Northwest Biotherapeutics (NWBO) R&D spending by quarter
Northwest Biotherapeutics' R&D spending was $5.7M in Q2 2026 (second quarter 2026), +17% from Q1 2026. Over the last 7 quarters it ranged from $4.9M (Q1 2026) to $10.5M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $5.7M | +17% | -23% |
| Q1 2026 | $4.9M | -13% | -42% |
| Q4 2025 | $5.6M | -25% | -47% |
| Q3 2025 | $7.5M | +0.3% | — |
| Q2 2025 | $7.4M | -11% | — |
| Q1 2025 | $8.4M | -21% | — |
| Q4 2024 | $10.5M | — | — |
Q2 2026 at a glance
Northwest Biotherapeutics, Q2 2026: revenue $807K (+516% year over year), net loss $15.4M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Northwest Biotherapeutics' R&D spending?
Northwest Biotherapeutics' R&D spending was $5.7M in Q2 2026 (second quarter 2026), +17% from Q1 2026.
How has Northwest Biotherapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $4.9M (Q1 2026) to $10.5M (Q4 2024).
Q2 2026 results → · How Northwest Biotherapeutics makes money →